These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32338875)

  • 1. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
    Zhang C; Wang X; Cheng R; Zhong Z
    Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma.
    Chen R; Yang J; Mao Y; Zhao X; Cheng R; Deng C; Zhong Z
    Biomacromolecules; 2023 Nov; 24(11):5371-5380. PubMed ID: 37801632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
    Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
    PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
    Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
    J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
    Guo B; Wei J; Wang J; Sun Y; Yuan J; Zhong Z; Meng F
    Acta Biomater; 2022 Jun; 145():200-209. PubMed ID: 35430336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma.
    Gu W; An J; Meng H; Yu N; Zhong Y; Meng F; Xu Y; Cornelissen JJLM; Zhong Z
    Adv Mater; 2019 Nov; 31(46):e1904742. PubMed ID: 31560141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
    Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
    J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib.
    Jackson S; Agbana P; Kim KB; Bae Y
    J Pharm Sci; 2022 Apr; 111(4):1172-1177. PubMed ID: 34551351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib.
    Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
    Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
    Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
    Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
    Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
    J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model.
    Varela-Moreira A; van Straten D; van Leur HF; Ruiter RWJ; Deshantri AK; Hennink WE; Fens MHAM; Groen RWJ; Schiffelers RM
    Int J Pharm X; 2020 Dec; 2():100049. PubMed ID: 32490374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
    Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
    Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
    Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
    J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
    Jun Y; Xu J; Kim H; Park JE; Jeong YS; Min JS; Yoon N; Choi JY; Yoo J; Bae SK; Chung SJ; Yeo Y; Lee W
    J Pharm Sci; 2020 Apr; 109(4):1615-1622. PubMed ID: 31945310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors.
    Gadalla HH; Lee S; Kim H; Armstrong AT; Fathalla D; Habib F; Jeong H; Lee W; Yeo Y
    J Control Release; 2022 Dec; 352():637-651. PubMed ID: 36349616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.
    Federspiel JD; Codreanu SG; Goyal S; Albertolle ME; Lowe E; Teague J; Wong H; Guengerich FP; Liebler DC
    Mol Cell Proteomics; 2016 Oct; 15(10):3233-3242. PubMed ID: 27503896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.